‌

US Patent 10227410 Heterodimeric antibodies that bind CD3 and PSMA

Patent 10227410 was granted and assigned to Xencor on March, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Xencor

Current Assignee

Xencor

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10227410

Date of Patent

March 12, 2019

Patent Application Number

15372360

Date Filed

December 7, 2016

Patent Citations Received

‌

US Patent 12129309 Heterodimeric antibodies that bind CD3 and CD38

‌

US Patent 11492407 Bispecific checkpoint inhibitor antibodies

‌

US Patent 11945880 Heterodimeric antibodies that bind CD3 and tumor antigens

‌

US Patent 11472890 Heterodimeric antibodies that bind ENPP3 and CD3

‌

US Patent 10858417 Heterodimeric proteins

‌

US Patent 10968276 Optimized anti-CD3 variable regions

‌

US Patent 11591401 Anti-CD28 compositions

...

Patent Primary Examiner

‌

Sean E Aeder

Patent abstract

The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10227410 Heterodimeric antibodies that bind CD3 and PSMA

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API